Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CHOLESTEROL-LOWERING AND THE USE OF HEALTH-CARE RESOURCES - RESULTS OF THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY
Autore:
PEDERSEN TR; KJEKSHUS J; BERG K; OLSSON AG; WILHELMSEN L; WEDEL H; PYORALA K; MIETTINEN T; HAGHFELT T; FAERGEMAN O; THORGEIRSSON G; JONSSON B; SCHWARTZ JS; THOMSEN H; NORDENO E; THOMSEN B; LYNGBORG K; ANDERSEN GS; NIELSEN F; TALLERUPHUUS U; MOGENSEN M; EGSTRUP K; SIMONSEN EH; SIMONSEN I; VEJBYCHRISTENSEN H; SOMMER L; EIDNER PO; KLARHOLT E; HENRIKSEN A; MELLEMGAARD K; LAUNBERG J; FRUERGAARD P; NIELSEN L; MADSEN EB; IBSEN H; ANDERSEN U; THYRRING L; THOMASSEN K; JENSEN G; RASMUSSEN SL; SKOV N; HANSEN KN; LARSEN ML; HAASTRUP B; HJAERE I; THURO A; SORENSEN K; LETH A; MUNCH M; WORCK R; NIELSEN B; THORN AG; PEDERSENBJERREGAARD O; FOURNAISE B; SIGURD B; ENK B; NIELSEN H; JACOBSEN L; SVENDSEN TL; NOEGHOLM A; MUNTER H; HAUNSO S; GRANDE P; ERIKSEN C; NIELSEN HH; PINDBORG T; PINDBORG J; TOST H; CHRISTIANSEN BD; OPPENHAGEN M; EGEDE F; HVIDT S; KJAERBY T; FLEMMING L; KLAUSEN I; VANHANEN H; STRANDBERG T; HOLTTA K; PASTERNAK A; OKSA H; SIITONEN L; RIMPI R; KESANIEMI A; JUUSTILA H; NISSILA A; SAVOLAINEN M; LILJA M; RANTALA A; RANTALA M; LAINE L; MANTYMAA L; NISSILA A; VIRKKALA L; EBELING T; HELIN M; LEHTO S; PALOMAKI P; RANTALA A; VOUTILAINEN E; MIETTINEN H; RAISANEN R; SALOKANNEL A; JANTUNEN A; HOGNASON J; THORSTEINSDOTTIR G; SIGURDSSON G; SVERRISSON JT; HANSTEEN V; KJELSBERG F; BERGET K; PETTERSEN R; RANDI E; HOLM T; GUNDERSEN T; ASLAKEN B; ANDRESEN EH; TORSVIK H; PETTERSEN R; FABER A; INDREBO T; OSE A; ROTERUD T; HOLSTLARSEN L; WAAGE K; HOLSTLARSEN E; HAEREM JW; AUKRUST P; TORP R; MAUSETH K; HALLARAKER A; GERDTS E; GRADEK G; NYGARD O; VANGEN EM; HANSEN HS; RESFSUM AM; LISTERUD S; GUNDERSRUD B; STENE AM; AAKERVIK O; KLUKKEN B; LORAAS A; FOSS PO; HAGA A; THORESEN L; DRIVENES A; LEM P; GABRIELSEN F; HESTAD S; RODE R; HAUG BK; SKJELVAN G; ELDORSEN E; YTREARNE K; RASMUSSEN K; NERMOEN I; GJESTVANG FT; CHRISTIANSEN L; WALBERG K; TJONNDAL HA; KULSENG B; ROKSETH R; NERGARD TV; ROE MO; TENSTAD O; LOFSNES IL; BERGSRUD U; MELBERG TH; VONBRANDIS C; HEGRENES L; BARVIK S; WOIE L; ABRAHAMSEN AM; AARSLAND T; SVANES H; NOER G; NORDLIE KE; HANEDALEN AE; OVERSKEID K; SANDVEI P; JOHANSEN A; JOHANSEN T; HOLM T; LARSEN CB; OSTHOLM E; HEGRESTAD S; REIKVAM A; SOGNEN E; STILIANOY E; HAWKES L; HOFF S; NORDVIK R; JORGENSEN C; HJERMANN I; LEREN P; NARVESTAD A; FAUSA D; GJESTVANG FT; BERGET K; NORDLAND B; BRUNMARK P; BIORKLUND H; FORSBERG H; NILSSON J; BERGSTROM B; LAAKSONEN I; VESTERMARK MB; MASCHER G; HAMMARSTROM E; TROSELL K; KARLSSON L; HALLSTROM L; STJERNA A; SLETTE MK; BERGLUND KP; LINDE B; AHLMARK G; SAETRE H; AHLBERG G; SUNDKVIST K; LOFMARK R; GUSTAFSSON PE; MICHAELI EW; GUSTAFSSON E; SKARFORS E; RUTER G; AKESSON L; WAGNER F; LJUNGDAHL L; WAGNER V; EDHAG O; VOURISALO D; HJELMSELL H; LUNDKVIST L; ANGMAN K; OLSSON A; SVENSSON O; KUYLENSTIERNA J; FRISENETTEFICH K; BERGMAN E; STROMBLAD H; JENSEN S; JONSSON E; LEVIN C; ODEBERG H; BENGTSSON PO; HOLMESSON E; HEDSTAND H; BOJO L; OBERG S; PERSSON S; CLINE C; LEKSELL H; WIRENSTAM UB; MOBERG B; EKSTRAND AB; NICOL P; MALMROS B; SAAW J; ARCINI N; KOBOSKO J; ANEVIK IG; GYLAND F; LUNDH B; WENNERHOLM M; OLSSON C; KJELLBERG J; FABIANSON K; FRASER T; BERGKVIST I; OLSSON AG; BERGDAHL B; FLUUR K; WARJESTAM S; SVENSSON KA; EKHOLM L; TOREBO E; RYBERG A; FRISELL J; HEDMAN A; VALLRUP L; ANDERSEN G; SUNDSTROM M; ALBERY K; FAGHER B; THULIN T; SVENSTAM I; NORRBY A; JAUP B; SVENSSON L; BJURMAN A; SKOGLUND E; DAHL G; KJELLSTROM T; JUHLIN P; SJOOBOQUIST M; SJOGREN A; LOOGNA E; JANSSON T; FRIDEN J; NILSSON O; ANDERSSON PO; HENRIKSSON C; ELLSTROM J; BRODERSSON H; LUNDQUIST L; ASLUND M; BOMAN K; JANSSON JH; NORRFORS B; HOGLUND C; LUNDBLAD M; EJDEBACK J; MALMBERG K; HOGSTROM S; STAHL L; LEIJD B; FALKENBERG C; BERGSTEN L; STROM S; ENGSTROM AC; PETZ I; LILJEFORS I; WENNERSTROM L; WIKLUND O; LINDEN T; BERGH CH; JONSTED K; BONNIER B; LUNDIN Y; MOLLER BH; LYCKSELL M; SODERSTROM M; HANSSON E; GILLGREN L; HALLEN C; STAKEBERG H; BORRETZEN J; HEDEN B; ANDERSSON K; JOHNSON O; SLUNGA L; JENSEN S; ELANDER B; LIDELL C; ANDERSSON PE; MARKLUND E; DAHLEN M; RUCKER F; LOFQVIST M; WANNBERG B; LIM BH; LARSSON O; ANDERSSON G; HANSSON A; GOWENIUS M; UGGELDAHL I; URSING D; HAMMARLUND P; TSUPPUKA E; MALMBERG L; GORANSSON K; HASSELGREN P; INBERG KM; PETTERSON S; ARLIN A; ULVENSTAM G; JOHANSSON S; WALLIN I; DUDAS K; ANDREASSON M; TORELUND G; LOVHEIM O; HEMMINGSON LO; GRUNDSTROM I; JULIAN DG; FURBERG C; THOMPSON S; LUBSEN J; SMITH WM; HUTTUNEN J; ROMO M; THYGESEN K; LEHTO S; MIETTINEN H; CROW R; CHRISTOPHERSEN B; BUCHMAN M; GRAN T; COOK J; GOMES D; BOCCUZZI S; COOK T; KRISTIANSON K;
Indirizzi:
AKER HOSP,DEPT MED,CARDIOL SECT N-0514 OSLO NORWAY
Titolo Testata:
Circulation
fascicolo: 10, volume: 93, anno: 1996,
pagine: 1796 - 1802
SICI:
0009-7322(1996)93:10<1796:CATUOH>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY HEART-DISEASE; COST-EFFECTIVENESS; CHOLESTYRAMINE; PREVENTION;
Keywords:
CHOLESTEROL; PREVENTION; CORONARY DISEASE; DRUGS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
25
Recensione:
Indirizzi per estratti:
Citazione:
T.R. Pedersen et al., "CHOLESTEROL-LOWERING AND THE USE OF HEALTH-CARE RESOURCES - RESULTS OF THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY", Circulation, 93(10), 1996, pp. 1796-1802

Abstract

Background Advances in the treatment of cardiovascular disease have increased costs; annual cardiovascular healthcare expenditure in the United States currently exceeds $100 billion. Physicians and third-partypayers need to assess the economic impact of treatments that reduce cardiovascular morbidity and mortality. Methods nod Results The Scandinavian Simvastatin Survival Study is a randomized, double-blind, placebo-controlled trial in which simvastatin reduced the risk of death by 30% (P=.0003) over the median follow-up period of 5.4 years in patientswith previous myocardial infarction or stable angina pectoris as a result of a 42% reduction in the risk of coronary deaths (P=.00001). In the present report, data prospectively collected from hospital admissions were analyzed to evaluate the impact of simvastatin on healthcare resource use and perform a cost-minimization analysis. In the placebo group (n=2223), there were 1905 hospitalizations (average duration, 7.9 days) for acute cardiovascular events or coronary revascularization procedures among 937 patients, whereas in the simvastatin group 1403 such hospitalizations (average 720 patients (all differences, P<.0001). The corresponding number of hospital days was 15 089 and 9951 in the two groups, respectively (34% reduction, P<.0001). In the United States, the resulting reduction in hospitalization costs over the 5.4 yearsof the trial would be $3872 per patient. reducing the effective cost of simvastatin by 58% to $0.28 per day. Conclusions In addition to reducing mortality and morbidity in coronary heart disease patients, simvastatin markedly reduces use of hospital services, thus offsetting most of its cost.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 20:34:33